


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		01-034	09/760,119
		<b>Applicant:</b>	
		Sarah S. Bacus	
		<b>Filing Date:</b>	<b>Group:</b>
		01/12/2001	1642

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAC	1.	Dannecker et al.; Induction of TGF-beta by an antiprogesterin in the human breast cancer cell line T-47D; Ann. Onc., Apr 1996; 7: 391 - 395.
	2.	Gillett et al.; Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma; J Pathol, Jan 1999; 187(2): 200-6.
	3.	Smith et al.; Primary chemotherapy in breast cancer; Biomed Pharmacother, Jan 1998; 52(3): 116-21.
	4.	Srivastava et al.; Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells; Anticancer Res, Nov 1998; 18(6A): 4003-10.
✓	5.	Vollmer et al.; Down-regulation of tenascin expression by antiprogesterins during terminal differentiation of rat mammary tumors; Cancer Res., Sep 1992; 52: 4642 - 4648.

EXAMINER	<i>John A. Ganello</i>	DATE CONSIDERED	<i>9/19/05</i>
----------	------------------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.